<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Suggested empiric parenteral regimens for acute bacterial arthritis in children age 3 months and older</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Suggested empiric parenteral regimens for acute bacterial arthritis in children age 3 months and older</h1>
<div class="graphic"><div class="figure"><div class="ttl">Suggested empiric parenteral regimens for acute bacterial arthritis in children age 3 months and older</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup> <colgroup span="2" width="40%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="3">Hemodynamically unstable children ≥3 months of age</td> </tr> <tr> <td rowspan="4"><strong>Coverage for <em>S. aureus</em> (MSSA and MRSA) and <em>Neisseria meningitidis</em></strong></td> <td class="subtitle2">Antimicrobial regimen*</td> <td class="subtitle2">Comment</td> </tr> <tr> <td>Three drug combination therapy: <ul class="decimal_heading"> <li>Vancomycin <strong>plus</strong></li> <li>Ceftriaxone <strong>plus</strong></li> <li><strong>One</strong> of the following: <ul> <li>Cefazolin</li> <li>Nafcillin</li> <li>Oxacillin</li> </ul> </li> </ul> </td> <td> <ul> <li>Cefazolin, nafcillin, or oxacillin is superior to vancomycin for MSSA</li> <li>Ceftriaxone provides coverage for <em>N. meningitidis</em></li> </ul> </td> </tr> <tr> <td class="indent1" colspan="2"><strong>or</strong></td> </tr> <tr> <td>Two drug combination therapy: <ul class="decimal_heading"> <li>Vancomycin <strong>plus</strong></li> <li>Cefepime</li> </ul> </td> <td> <ul> <li>Cefepime provides activity against MSSA and <em>N. meningitidis</em></li> </ul> </td> </tr> <tr> <td class="subtitle1" colspan="3">Hemodynamically stable children ≥3 months of age</td> </tr> <tr> <td rowspan="5"><strong>Coverage for <em>S. aureus</em></strong></td> <td class="subtitle2">Antibiotic agent*</td> <td class="subtitle2">Comment</td> </tr> <tr> <td colspan="2"><strong>&lt;10% of community <em>S. aureus</em> isolates are MRSA</strong><sup>¶</sup></td> </tr> <tr> <td class="indent1">One of the following: <ul class="decimal_heading"> <li>Cefazolin</li> <li>Nafcillin</li> <li>Oxacillin</li> </ul> </td> <td> <ul> <li>Cefazolin also provides coverage for <em>Kingella kingae</em> (eg, for children 6 to 36 months of age who attend day care or had oral ulcers before onset of musculoskeletal symptoms)</li> </ul> </td> </tr> <tr> <td colspan="2"><strong>≥10% of community <em>S. aureus</em> isolates are MRSA</strong><sup>¶</sup></td> </tr> <tr> <td class="indent1">Clindamycin or vancomycin</td> <td> <ul> <li>Vancomycin is preferred: <ul> <li>For life-threatening infections (in combination with nafcillin/oxacillin pending susceptibility results)</li> <li>If ≥10% of community <em>S. aureus</em> isolates are clindamycin-resistant<sup>¶</sup></li> <li>For children with prosthetic joints (CoNS)</li> </ul> </li> </ul> </td> </tr> <tr> <td class="indent1" colspan="3"><strong>plus</strong></td> </tr> <tr> <td rowspan="10"><strong>Additional coverage as clinically indicated</strong></td> <td class="subtitle2">Indication</td> <td class="subtitle2">Antibiotic agent(s)*</td> </tr> <tr> <td>Gram-negative organisms on Gram stain</td> <td> <ul> <li>Cefotaxime, ceftriaxone, or cefuroxime</li> </ul> </td> </tr> <tr> <td>Penetrating trauma or history of penetrating trauma (polymicrobial, including <em>P. aeruginosa</em>)</td> <td> <ul> <li>Cefepime monotherapy,<sup>Δ</sup> or</li> <li>Combination therapy<sup>◊</sup> with: <ul> <li>Either cefepime or ceftazidime <strong>plus</strong></li> <li>Either clindamycin or vancomycin</li> </ul> </li> </ul> </td> </tr> <tr> <td>Age 6 to 36 months and day care attendance or history of oral ulcers before onset of musculoskeletal symptoms (<em>K. kingae</em>)</td> <td> <ul> <li>Use cefazolin for antistaphylococcal coverage, if possible<sup>§</sup></li> </ul> </td> </tr> <tr> <td>Incomplete Hib immunization in child &lt;2 years of age in area with low rates of Hib immunization (Hib)</td> <td rowspan="3"> <ul> <li>Cefotaxime or ceftriaxone</li> </ul> </td> </tr> <tr> <td>Incomplete pneumococcal immunization in a child &lt;2 years of age, or high-risk condition for invasive pneumococcal disease<sup>¥</sup>, or antibiotic therapy within 4 weeks of diagnosis of bacterial arthritis (penicillin-nonsusceptible <em>Streptococcus pneumoniae</em>)</td> </tr> <tr> <td>Sickle cell disease or related hemoglobinopathies (<em>Salmonella</em>)</td> </tr> <tr> <td>Recent GI surgery or complex urinary tract anatomy (enteric gram-negative organism)</td> <td> <ul> <li>One of the following: <ul> <li>Cefotaxime</li> <li>Ceftriaxone</li> <li>Cefepime (if <em>P. aeruginosa</em> is a concern)</li> </ul> </li> </ul> </td> </tr> <tr> <td>Sexually active adolescent (<em>N. gonorrhoeae</em>)<sup>‡</sup></td> <td> <ul> <li>Ceftriaxone plus presumptive treatment for chlamydia</li> </ul> </td> </tr> <tr> <td>Injection drug user (<em>P. aeruginosa</em>)</td> <td> <ul> <li>Ceftazidime</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes"><p>MSSA: methicillin-susceptible S. aureus; 
		MRSA: methicillin-resistant <em>S. aureus</em>; 
		CoNS: coagulase-negative <em>S. aureus</em>;
		Hib: <em>Haemophilus influenzae</em> type b;
		GI: gastrointestinal.</p>
<p>* Refer to UpToDate topic on treatment of bacterial arthritis in children for dosing.</p>
<p>¶ Other experts may use different thresholds for methicillin or clindamycin resistance.</p>
<p>Δ Provides coverage for <em>P. aeruginosa</em> and MSSA.</p>
<p><span class="lozenge">◊</span> Provides coverage for <em>P. aeruginosa</em> and MRSA.</p>
<p>§ We do not generally provide initial empiric coverage for <em>K. kingae</em> in young children if <em>K. kingae</em> coverage requires two drugs; we add coverage for <em>K. kingae</em> if the child does not improve.*</p>
<p>¥ Refer to UpToDate topic on pneumococcal vaccination in children for details.</p>
	
	‡ Refer to UpToDate topic on disseminated gonococcal infection for details.</div><div id="graphicVersion">Graphic 112013 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
